WASHINGTON, D.C. – This week, the U.S. Senate Committee on Appropriations considered and approved its draft FY25 appropriations bill that includes significant increases for the National Institutes of Health (NIH), increases for federal cancer research funding at the National Cancer Institute (NCI) and an increase for the Centers for Disease Control and Prevention’s (CDC) Division of Cancer Prevention and Control.
The Senate spending bill includes: $50.351 billion for NIH, which is an increase of $1.77 billion from FY24 levels, including $7.49 billion for the NCI, which is an increase of $266 million over FY24. The bill also includes $1.5 billion for the Advanced Research Projects Agency for Health (ARPA-H), which is the same as FY24 levels. The report recommends increasing funding for CDC’s Division of Cancer Prevention and Control (DCPC) by $15 million, from $410 million in FY24 to $425 million in FY25, this includes an increase to the National Breast & Cervical Cancer Early Detection Program.
In response, Dr. Karen E. Knudsen, CEO of the American Cancer Society and the American Cancer Society Cancer Action Network released the following statement:
“We are grateful to see the significant increase in funding for NIH and increase for NCI. We appreciate the Committee’s bipartisan commitment to our nation’s critical investment in cancer research. These increases will help bring us closer to our goal of ending cancer as we know it, for everyone.
“We are also thankful for the Senate’s work to provide level funding for ARPA-H, and continued funding for cancer prevention and screening programs at the CDC. The funding for these institutions will help us continue to save lives and protect our nation’s status as a leader in global health research.
“We encourage Congress to continue working towards a final bill that will provide sustained, increased investments which are critical to advancing the cancer treatments and cures of the future.”
###